Continuous Glucose Monitoring for Diabetes

N/A

Waitlist Available

Led By Tresa McNeal, MD

Research Sponsored by Baylor Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 10 days

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether or not systematic continuous glucose monitoring is an effective treatment option for patients with diabetes who are receiving care in a hospital setting.

Who is the study for?

This trial is for adults with diabetes who are hospitalized and expected to stay at least two more days. Participants must be willing to wear a CGM device and not use high doses of acetaminophen. It's not for pregnant or lactating women, those planning surgery within 48 hours, patients with certain skin conditions or allergies, active substance abusers, organ transplant recipients, or those with severe medical conditions.

What is being tested?

The study tests the Dexcom Gen6 continuous glucose monitoring (CGM) device in hospitalized diabetic patients outside the ICU. The goal is to see if this newer CGM technology can improve blood sugar control and reduce hypoglycemic events compared to older devices.

What are the potential side effects?

Potential side effects may include skin irritation or allergic reactions where the CGM device attaches due to adhesive or disinfectants used on the skin.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 10 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 10 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Hypoglycemia Events during hospitalization

Secondary study objectives

Number of Hyperglycemia Events during hospitalization

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Treatment GroupExperimental Treatment1 Intervention

Treatment Group subjects will wear the CGM device during their hospitalization, up to 10 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.

Group II: Control GroupActive Control1 Intervention

Control Group subjects will wear the CGM device during their hospitalization, up to 10 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.

Do I qualify?Apply below to find out